Order Article Reprints

Nishihara S, Yamaoka T, Ishikawa F, Ohmori T, Ando K, Kusumoto S, Kishino Y, Manabe R, Hasebe Y, Sagara H, et al. Diverse Mechanisms of Resistance against Osimertinib, a Third-Generation EGFR-TKI, in Lung Adenocarcinoma Cells with an EGFR-Activating Mutation. Cells. 2022; 11(14):2201. https://doi.org/10.3390/cells11142201

Nishihara, Shigetoshi, Toshimitsu Yamaoka, Fumihiro Ishikawa, Tohru Ohmori, Koichi Ando, Sojiro Kusumoto, Yasunari Kishino, Ryo Manabe, Yuki Hasebe, Hironori Sagara, and et al. 2022. "Diverse Mechanisms of Resistance against Osimertinib, a Third-Generation EGFR-TKI, in Lung Adenocarcinoma Cells with an EGFR-Activating Mutation" Cells 11, no. 14: 2201. https://doi.org/10.3390/cells11142201

Nishihara, S., Yamaoka, T., Ishikawa, F., Ohmori, T., Ando, K., Kusumoto, S., Kishino, Y., Manabe, R., Hasebe, Y., Sagara, H., Yoshida, H., & Tsurutani, J. (2022). Diverse Mechanisms of Resistance against Osimertinib, a Third-Generation EGFR-TKI, in Lung Adenocarcinoma Cells with an EGFR-Activating Mutation. Cells, 11(14), 2201. https://doi.org/10.3390/cells11142201